Overview
A recent preclinical study revealed that a gentle, chemotherapy-free conditioning regimen combined with donor blood stem cells and pancreatic islets can reverse autoimmune type 1 diabetes in mice. This strategy induces stable mixed immune chimerism and restores long-term glucose control without graft-versus-host disease. Fonte
Method
Researchers tested an antibody-based conditioning protocol — including anti-CD117, transient T-cell depletion, JAK1/2 inhibition, and low-dose irradiation — followed by mismatched hematopoietic stem-cell transplantation together with donor islets. The treatment reprogrammed the immune system to accept donor cells and suppress the autoimmune attack. Fonte
Main findings
- Prediabetic mice achieved durable mixed hematopoietic chimerism and were fully protected from developing type 1 diabetes. Fonte
- Mice with established diabetes were cured after receiving the combined transplant. Fonte
- No significant graft-versus-host disease occurred during the long-term follow-up. Fonte
Clinical relevance
The dual approach targets both the autoimmune destruction of beta cells and the loss of insulin production. Because some components of the regimen are already used clinically for other purposes, researchers see realistic potential for human translation, pending safety and feasibility trials. Fonte
Challenges ahead
Human application requires solving the limited availability of donor islets and ensuring long-term safety. Stem-cell-derived islets may help address supply issues, but further validation is needed. Fonte
Conclusion
The study offers strong proof that type 1 diabetes can be reversed through an immune-reset strategy combined with islet replacement. Although significant hurdles remain, the findings represent a promising pathway toward durable remission. Fonte
Copyright © Tutti i diritti sono riservati – Salute33